Evidence map›Paper›PMID 33087330›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2021

Expanded Low Allele Frequency

Jonathan M Loree, Anthony Dowers, Dongsheng Tu, Derek J Jonker, Daniel L Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R Zalcberg, Malcolm J Moore and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Encorafenib plus cetuximab for the treatment ofTherapeutic advances in gastroenterology · 2022
    Review
  15. Clinical and Functional Characterization of AtypicalClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 4 countries.

Jonathan M LoreeBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-8189-2132
Anthony DowersThe University of Melbourne, Melbourne, Victoria, Australia.
Dongsheng TuCanadian Cancer Trials Group, Kingston, Ontario, Canada.
Derek J JonkerThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
Daniel L EdelsteinSysmex-Inostics, Baltimore, Maryland.
Hannah QuinnSysmex-Inostics, Baltimore, Maryland.
Frank HoltrupSysmex-Inostics, Baltimore, Maryland.
Timothy PriceQueen Elizabeth Hospital, Adelaide, South Australia, Australia.
John R ZalcbergMonash University, Melbourne, Victoria, Australia.
Malcolm J MooreBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
Christos S KarapetisFlinders University, Adelaide, South Australia, Australia.
Chris J O'CallaghanCanadian Cancer Trials Group, Kingston, Ontario, Canada.
Paul WaringThe University of Melbourne, Melbourne, Victoria, Australia.
Hagen F KenneckeVirginia Mason Cancer Institute, Seattle, Washington.
Stanley R HamiltonCity of Hope, Los Angeles, California.
Scott KopetzUniversity of Texas, MD Anderson Cancer Center, Houston, Texas. skopetz@mdanderson.org.
Sysmex (Japan) · JPCanadian Cancer Society · CAThe University of Melbourne · AUUniversity of British Columbia Hospital · CACity of Hope · USMonash University · AUOttawa Hospital · CAQueen Elizabeth Hospital · AUThe University of Texas MD Anderson Cancer Center · USUniversity of South Australia · AUVirginia Mason Medical Center · US

Funding

Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsiesR01CA218230 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2018 to 2022
$3.3M
Tumor Heterogeneity and Acquired Resistance to EGFR InhibitionR01CA184843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAMILTON, STANLEY R., KOPETZ, SCOTT · 2015 to 2019
$3.2M
Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HONG, DAVID S., KOPETZ, SCOTT · 2014 to 2018
$1.7M
Stress Signaling Pathways and Resistance in Colorectal CancerR01CA172670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2013 to 2017
$1.6M
NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA172670NCI NIH HHS R01 CA184843NCI NIH HHS R01 CA187238NCI NIH HHS R01 CA218230
6 · The paper itself

Abstract

purposeExpanded PATIENTS AND

methodsCO.17 trial compared cetuximab versus best supportive care (BSC) in

results

conclusionsWe establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCetuximabColorectal NeoplasmsDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleGene FrequencyGTP PhosphohydrolasesHumansMaleMembrane ProteinsMiddle AgedMutationBiomarkers, TumorBRAF protein, humanCetuximabGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID33087330
PMCPMC7785657
OpenAlexW3094254214

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.